Pay in 4 interest-free payments of $5.99 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Regulatory status: BPC-157 is not FDA-approved and was scheduled for FDA advisory committee discussion in July 2026
(1) S Seiwerth, R Rucman, B Turkovic, M Sever, et al (2018)
Every new approval expands the market Better insurance coverage- Right now, many plans dont cover GLP-1s for obesity
The result is lower appetite, smaller portions, and steady weight loss over months
Degenerative joint disease, osteoarthritis and overweight all go hand in hand
They had a body mass index (BMI) of at least 30 on the date of treatment initiation or during the latest available primary care visit, or a BMI of at least 27 with one or more weight-related comorbidities such as hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease
